Jonathan Young Akero Therapeutics, Inc. (AKRO) insider trading activity

Jonathan Young is Chief Operating Officer of Akero Therapeutics, Inc.. Currently has a direct ownership of 196,594 shares of AKRO, which is worth approximately $11 Million. The most recent transaction as insider was on Mar 13, 2024, when has been sold 651 shares (Common Stock) at a price of $28.33 per share, resulting in proceeds of $18,442. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 197K

1.97% 3M change

20.36% 12M change

Total Value Held $11 Million

Jonathan Young Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 13 2024	SELL Open market or private sale	$18,442 $28.33 p/Share	651 Reduced 0.24%	268,306 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	$51,659 $0.62 p/Share	83,321 Added 23.65%	268,957 Common Stock
Dec 27 2023	SELL Open market or private sale	$129,936 $24.0 p/Share	5,414 Reduced 2.84%	185,131 Common Stock
Dec 27 2023	BUY Exercise of conversion of derivative security	$34,433 $6.36 p/Share	5,414 Added 2.76%	190,545 Common Stock
Dec 14 2023	SELL Open market or private sale	$11,272 $20.76 p/Share	543 Reduced 0.29%	185,131 Common Stock
Dec 08 2023	BUY Grant, award, or other acquisition	-	32,497 Added 14.9%	185,674 Common Stock
Nov 17 2023	SELL Open market or private sale	$440,400 $14.68 p/Share	30,000 Reduced 16.38%	153,177 Common Stock
Oct 02 2023	SELL Open market or private sale	$25,039 $51.1 p/Share	490 Reduced 0.27%	183,177 Common Stock
Oct 02 2023	BUY Exercise of conversion of derivative security	$10,339 $21.1 p/Share	490 Added 0.27%	183,667 Common Stock
Sep 13 2023	SELL Open market or private sale	$28,291 $50.34 p/Share	562 Reduced 0.31%	183,177 Common Stock
Jun 13 2023	SELL Open market or private sale	$29,676 $55.16 p/Share	538 Reduced 0.29%	183,739 Common Stock
Mar 10 2023	SELL Payment of exercise price or tax liability	$27,559 $43.47 p/Share	634 Reduced 0.34%	184,277 Common Stock
Jan 03 2023	SELL Open market or private sale	$479,575 $54.64 p/Share	8,777 Reduced 4.53%	184,911 Common Stock
Jan 03 2023	BUY Exercise of conversion of derivative security	$5,441 $0.62 p/Share	8,777 Added 4.34%	193,688 Common Stock
Dec 27 2022	SELL Open market or private sale	$619,625 $49.57 p/Share	12,500 Reduced 6.41%	182,449 Common Stock
Dec 27 2022	BUY Exercise of conversion of derivative security	$43,625 $3.49 p/Share	12,500 Added 6.03%	194,949 Common Stock
Dec 09 2022	BUY Grant, award, or other acquisition	-	19,195 Added 9.52%	182,449 Common Stock
Oct 25 2022	SELL Open market or private sale	$559,000 $44.72 p/Share	12,500 Reduced 7.11%	163,254 Common Stock
Oct 25 2022	BUY Exercise of conversion of derivative security	$79,500 $6.36 p/Share	12,500 Added 6.64%	175,754 Common Stock
Jan 07 2022	BUY Exercise of conversion of derivative security	$17,201 $0.62 p/Share	27,744 Added 14.53%	163,254 Common Stock
Nov 04 2021	SELL Open market or private sale	$151,333 $24.33 p/Share	6,220 Reduced 4.39%	135,510 Common Stock
Nov 03 2021	SELL Open market or private sale	$455,791 $24.27 p/Share	18,780 Reduced 11.7%	141,730 Common Stock
Sep 01 2021	SELL Open market or private sale	$300,500 $24.04 p/Share	12,500 Reduced 7.23%	160,510 Common Stock
Jul 15 2021	BUY Exercise of conversion of derivative security	$5,580 $0.62 p/Share	9,000 Added 4.94%	173,010 Common Stock
Jun 01 2021	SELL Open market or private sale	$80,163 $26.24 p/Share	3,055 Reduced 1.83%	164,010 Common Stock

Jonathan Young

Chief Operating Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Value

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO

Account